Monitor MIST Phase 2b enrollment completion (mid-2026) and topline data (H2 2027) as the primary catalysts. The IPO removes near-term financing risk, shifting focus to clinical execution. Watch for any enrollment delays or safety signals in upcoming data presentations at EULAR (June 6, 2026).
Price Chart
Executive Summary
Avalyn Pharma reported Q1 2026 results showing a net loss of $26.9M, wider than the $17.5M loss in Q1 2025, driven by increased R&D spend on its Phase 2b MIST trial and Phase 2 AURA trial. The company highlighted its upsized IPO raising $345M in gross proceeds, extending its cash runway into 2029, and reiterated pipeline milestones including MIST enrollment completion mid-2026 and topline data in H2 2027. As a pre-revenue clinical-stage biotech, the filing contains no revenue or EPS surprises to trade on — the stock will move on pipeline catalysts and cash runway updates, not quarterly financials.
Key Facts
- Net loss of $26.9M for Q1 2026 vs $17.5M in Q1 2025
- Cash, cash equivalents, and marketable securities of $123.1M as of March 31, 2026, excluding IPO proceeds
- Upsized IPO in May 2026 raised gross proceeds of $345.0M (19,166,667 shares at $18.00)
- Net IPO proceeds of ~$316.1M extend cash runway into 2029
- R&D expenses increased to $22.9M from $15.3M YoY, driven by AP01 Phase 2b and AP02 Phase 2 trials
- MIST Phase 2b trial of AP01 in PPF on track to complete enrollment mid-2026, topline data expected H2 2027
- AURA Phase 2 trial of AP02 in IPF enrollment underway, topline data expected late 2027
- Phase 1 trial of AP03 (fixed-dose combination) on track to initiate by end of 2026
- No revenue reported — pre-revenue clinical-stage company
Financial Impact
Net loss widened by $9.4M YoY to $26.9M; cash burn rate ~$9.0M/month in Q1 2026; post-IPO cash runway extended into 2029
Risk Factors
- Clinical trial enrollment delays or unexpected safety/efficacy data
- Dilution from future equity financings if cash runway shortens
- Competitive landscape changes in pulmonary fibrosis treatments
- Regulatory setbacks in Phase 2b or Phase 2 trials
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254581 |
| Document: ck0001540171-20260603.htm | 0001193125-26-254581 |
| Document: 0001193125-26-254581-index-headers.html | 0001193125-26-254581 |
| Document: 0001193125-26-254581-index.html | 0001193125-26-254581 |
| Document: 0001193125-26-254581.txt | 0001193125-26-254581 |
| 8-K Data (Synthetic) | 0001193125-26-254581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | Press Release | $31.62 $28.32 | ▼ −10.44% | ▼ −9.42% | $27.14 (−14.17%) |
Aug 16, 2026 10w ago | Institutional Cluster | $38.25 $37.69 | ▼ −1.46% | ▼ −0.27% | $27.14 (−29.05%) |
Aug 12, 2026 10w ago | 8-K | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.14 (−27.39%) |
Aug 12, 2026 10w ago | Press Release | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.14 (−27.39%) |
Jun 17, 2026 18w ago | 8-K | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.14 (−7.40%) |
Jun 17, 2026 18w ago | Press Release | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.14 (−7.40%) |
Jun 3, 2026 20w ago | 8-K | $26.40 $28.53 | ▲ +8.07% | ▲ +11.89% | $27.14 (+2.80%) |
May 5, 2026 24w ago | Press Release | $27.71 $29.90 | ▲ +7.90% | ▲ +6.77% | $27.14 (−2.06%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.14 (−6.64%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.14 (−6.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers